Afficher la notice abrégée

Immune Profiling Reveals the T-Cell Effect of Ocrelizumab in Early Relapsing-Remitting Multiple Sclerosis

dc.rights.licenseopenen_US
dc.contributor.authorGARCIA, Alexandra
dc.contributor.authorDUGAST, Emilie
dc.contributor.authorSHAH, Sita
dc.contributor.authorMORILLE, Jeremy
dc.contributor.authorLEBRUN-FRENAY, Christine
dc.contributor.authorTHOUVENOT, Eric
dc.contributor.authorDE SEZE, Jerome
dc.contributor.authorLE PAGE, Emmanuelle
dc.contributor.authorVUKUSIC, Sandra
dc.contributor.authorMAUROUSSET, Aude
dc.contributor.authorBERGER, Eric
dc.contributor.authorCASEZ, Olivier
dc.contributor.authorLABAUGE, Pierre
hal.structure.identifierNeurocentre Magendie : Physiopathologie de la Plasticité Neuronale [U1215 Inserm - UB]
dc.contributor.authorRUET, Aurelie
dc.contributor.authorRAPOSO, Catarina
dc.contributor.authorBAKDACHE, Fabien
dc.contributor.authorBUFFELS, Regine
dc.contributor.authorLE FRÈRE, Fabienne
dc.contributor.authorNICOT, Arnaud
dc.contributor.authorWIERTLEWSKI, Sandrine
dc.contributor.authorGOURRAUD, Pierre-Antoine
dc.contributor.authorBERTHELOT, Laureline
dc.contributor.authorLAPLAUD, David
dc.date.accessioned2024-02-20T15:43:48Z
dc.date.available2024-02-20T15:43:48Z
dc.date.issued2023-02-21
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/188268
dc.description.abstractEnBACKGROUND AND OBJECTIVES: Ocrelizumab (OCR), a humanized anti-CD20 monoclonal antibody, is highly efficient in patients with relapsing-remitting multiple sclerosis (RR-MS). We assessed early cellular immune profiles and their association with disease activity at treatment start and under therapy, which may provide new clues on the mechanisms of action of OCR and on the disease pathophysiology. METHODS: A first group of 42 patients with an early RR-MS, never exposed to disease-modifying therapy, was included in 11 centers participating to an ancillary study of the ENSEMBLE trial (NCT03085810) to evaluate the effectiveness and safety of OCR. The phenotypic immune profile was comprehensively assessed by multiparametric spectral flow cytometry at baseline and after 24 and 48 weeks of OCR treatment on cryopreserved peripheral blood mononuclear cells and analyzed in relation to disease clinical activity. A second group of 13 untreated patients with RR-MS was included for comparative analysis of peripheral blood and CSF. The transcriptomic profile was assessed by single-cell qPCRs of 96 genes of immunologic interest. RESULTS: Using an unbiased analysis, we found that OCR as an effect on 4 clusters of CD4+ T cells: one corresponding to naive CD4+ T cells was increased, the other clusters corresponded to effector memory (EM) CD4+CCR6- T cells expressing homing and migration markers, 2 of them also expressing CCR5 and were decreased by the treatment. Of interest, one CD8+ T-cell cluster was decreased by OCR corresponding to EM CCR5-expressing T cells with high expression of the brain homing markers CD49d and CD11a and correlated with the time elapsed since the last relapse. These EM CD8+CCR5+ T cells were enriched in the CSF of patients with RR-MS and corresponded to activated and cytotoxic cells. DISCUSSION: Our study provides novel insights into the mode of action of anti-CD20, pointing toward the role of EM T cells, particularly a subset of CD8 T cells expressing CCR5. Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
dc.description.sponsorshipObservatoire Français de la Sclérose en Plaquesen_US
dc.language.isoENen_US
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/us/*
dc.subject.enAntibodies
dc.subject.enMonoclonal
dc.subject.enHumanized
dc.subject.enHumans
dc.subject.enLeukocytes
dc.subject.enMononuclear
dc.subject.enMultiple Sclerosis
dc.subject.enRelapsing-Remitting
dc.subject.enOcrelizumab
dc.title.enImmune Profiling Reveals the T-Cell Effect of Ocrelizumab in Early Relapsing-Remitting Multiple Sclerosis
dc.title.alternativeNeurol Neuroimmunol Neuroinflammen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1212/NXI.0000000000200091en_US
dc.subject.halSciences du Vivant [q-bio]/Neurosciences [q-bio.NC]en_US
dc.identifier.pubmed36810163en_US
bordeaux.journalNeurology(R) neuroimmunology & neuroinflammationen_US
bordeaux.volume10en_US
bordeaux.hal.laboratoriesNeurocentre Magendie - U1215en_US
bordeaux.issue3en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamRelations glie-neuroneen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exportfalse
dc.rights.ccCC BY-NC-NDen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Neurology(R)%20neuroimmunology%20&%20neuroinflammation&rft.date=2023-02-21&rft.volume=10&rft.issue=3&rft.au=GARCIA,%20Alexandra&DUGAST,%20Emilie&SHAH,%20Sita&MORILLE,%20Jeremy&LEBRUN-FRENAY,%20Christine&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Nom:
MAGENDIE_NeurolNeuroimmunolNeu ...
Taille:
1.384Mo
Format:
PDF
Voir/Ouvrir
Thumbnail
Nom:
license_rdf
Taille:
811octets
Format:
application/rdf+xml
Voir/Ouvrir

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée